Please assess the completion status of the following clinical trial:

Trial Title: Argatroban Versus Lepirudin in Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Thrombocytopenia suspicious for HIT with decrease in platelet count \>50% from baseline obtained at hospital admission~* 4 T´s score for HIT probability \>3 AND/OR positive ELISA for HIT~* Age ≥18 years~* Informed consent (if applicable)~Exclusion Criteria:~* Transient thrombocytopenia due to intraoperative bleeding~* Active bleeding~* Intracranial operations~* Liver dysfunction with spontaneous aPTT\> 60 sec.~* History of adverse events or sensitivity against study drugs~* Pregnancy~* Age\<18 years~* Preexisting psychiatric/neurologic disorders with long-term inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PR1 (Type: ACTIVE_COMPARATOR): Patients treated with Argatroban (Argatra®), a direct thrombin inhibitor
- PR2 (Type: ACTIVE_COMPARATOR): Patients treated with Lepirudin (Refludan®), a direct thrombin inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).